Business Performance - In 2024, the company's main business segments generated a total revenue of CNY 2,273.76 million, accounting for 87.10% of total revenue, a decrease of 23.79% year-on-year [1] - The breakdown of revenue by segment is as follows: - Traditional Chinese Medicine (TCM): CNY 1,605.54 million (61.50%) - Chemical drugs: CNY 276.85 million (10.61%) - Chain pharmacy wholesale and retail: CNY 391.37 million (14.99%) - Health business: CNY 212.13 million (8.13%) [1] Product Development - The "Xuefu Zhuyu Oral Liquid" is a key product derived from a classic formula, recognized with multiple awards, including the National Science and Technology Progress Award [1] - In 2024, this product was selected for centralized procurement, which is expected to enhance its market share [2] Cost Control Measures - The company is addressing rising costs of herbal materials through several strategies: - Establishing GAP bases for stable supply of key herbs - Utilizing data analysis for demand forecasting and optimizing procurement [3] - Enhancing supply chain management and internal efficiency to reduce costs [3] Chemical Drug Segment - The chemical drug segment achieved a revenue of CNY 276.85 million in 2024, representing 10.61% of total revenue [4] - Key products include anti-tumor and immune-regulating drugs, with significant sales growth in specific items like injection RNA [4][6] - The company is focusing on deep market penetration and academic promotion to expand its market share [6] Retail and Wholesale Business - The chain pharmacy segment generated CNY 391.37 million in revenue, accounting for 14.99% of total revenue [8] - Membership increased by 18,300, totaling 1,189,000 members, with a net addition of 6 stores [8] - The company is enhancing online sales through major e-commerce platforms and implementing O2O strategies [9] Investment and Shareholder Returns - The company holds 20.05% of Guangfa Securities, its largest investment, enhancing its capital position [10] - A cash dividend of CNY 591 million is planned for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000623 证券简称：吉林敖东 公告编号：2025-025 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告 ...

第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码:000623 证券简称:吉林敖东 公告编号:2025-024 吉林敖东药业集团股份有限公司 一、董事会会议召开情况 1．吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十七次会议通知以书面方式于2025年4月18日发出。 2．会议于2025年4月29日在公司六楼会议室以现场方式召开。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券 报》《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《公司2025年 第一季度报告》（公告编号：2025-025）。 2．审议《关于聘任王超先生为公司副总经理的议案》 表决结果：通过。同意票9票，反对票0票，弃权票0票。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券报》 《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《关于聘任公司副 3．本次会议应到会董事9名，实际参加会议现场表决董事9名。 4．会议由公司董 ...

吉林敖东：一季度归母净利润5.17亿元，同比增长259.75% 金十数据4月29日讯，吉林敖东公告，2025年第一季度实现营业收入6.23亿元，同比下降27.71%；归属 于上市公司股东的净利润5.17亿元，同比增长259.75%；基本每股收益0.4396元。 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥622,624,001.54, a decrease of 27.71% compared to ¥861,336,047.60 in the same period last year[4] - Net profit attributable to shareholders increased by 259.75% to ¥516,839,939.37 from ¥143,665,579.44 year-on-year[4] - Basic and diluted earnings per share rose by 244.24% to ¥0.4396 from ¥0.1277 in the same period last year[4] - Net profit for the current period is ¥516,513,643.37, compared to ¥132,653,063.68 in the previous period, representing a significant increase[19] - Earnings per share (EPS) for the current period is ¥0.4396, up from ¥0.1277 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥55,946,098.42, a 538.76% increase from -¥12,751,058.81 in the previous year[4] - Net cash flow from operating activities was $55,946,098.42, a significant improvement compared to a negative cash flow of $12,751,058.81 in the previous period[21] - Cash inflow from investment activities totaled $714,385,824.50, up from $125,583,727.14 in the prior period[21] - Net cash flow from investment activities was negative at -$57,839,340.16, compared to -$88,593,367.85 previously[21] - Cash inflow from financing activities amounted to $680,165,022.64, a decrease from $1,740,458,808.05 in the last period[22] - Net cash flow from financing activities was -$39,769,994.80, contrasting with a positive flow of $13,396,454.21 in the previous period[22] - The ending balance of cash and cash equivalents was $1,064,016,449.93, down from $1,631,979,783.39 at the end of the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥33,511,130,541.92, reflecting a 1.54% increase from ¥33,001,896,399.52 at the end of the previous year[4] - Total assets amount to ¥33,511,130,541.92, an increase from ¥33,001,896,399.52 in the previous period[17] - Total liabilities are ¥3,830,632,233.59, compared to ¥3,719,663,017.59 in the previous period, reflecting a rise[17] - The company’s goodwill and intangible assets are reported at ¥466,307,167.58, up from ¥437,315,884.41 in the previous period[16] Investment and Income - The company's investment income surged by 90.00% to ¥507,603,747.81 compared to ¥267,154,606.73 in the previous year[9] - The fair value change income was ¥7,289,911.33, a significant recovery from a loss of -¥202,651,117.19 in the same period last year, marking a 103.60% increase[9] Operating Costs and Expenses - The company reported a 37.78% reduction in operating costs, totaling ¥329,277,082.41 compared to ¥529,178,611.99 in the previous year[8] - Total operating costs for the current period are ¥622,063,638.81, down 25.4% from ¥834,140,687.01 in the previous period[18] - Research and development expenses decreased by 30.74% to ¥13,116,487.67 from ¥18,938,606.15 year-on-year[8] - Research and development expenses for the current period are ¥13,116,487.67, a decrease from ¥18,938,606.15 in the previous period[18] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 67,022[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 27.35% of shares, totaling 327,080,749 shares[11] - The total number of preferred stock shareholders at the end of the reporting period is not applicable[13] Other Information - The company has not disclosed any new product or technology developments in this reporting period[14] - There are no significant mergers or acquisitions reported during this period[14] - The company has not provided specific future outlook or performance guidance in the current report[14]

证券代码:000623 证券简称:吉林敖东 公告编号: 2025-026 吉林敖东药业集团股份有限公司 关于聘任公司副总经理的公告 特此公告。 附件：王超先生简历。 吉林敖东药业集团股份有限公司董事会 2025 年 4 月 30 日 1 吉林敖东药业集团股份有限公司（下称"公司"）于 2025 年 4 月 29 日召开 第十一届董事会第十七次会议，审议通过了《关于聘任王超先生为公司副总经理 的议案》。结合市场环境、医药行业发展以及公司发展阶段，根据《公司法》《公 司章程》等相关规定，经总经理郭淑芹提名，公司董事会提名委员会审查，公司 董事会研究决定聘任王超先生担任公司副总经理，由王超先生负责公司整体医药 产品的战略统筹、渠道精耕、产销协同、品牌重塑等工作。任期自董事会会议审 议通过之日起至第十一届董事会任期届满为止。 王超先生不存在《公司法》《深圳证券交易所股票上市规则》等法律法规及 《公司章程》规定禁止任职的情形。公司董事会聘任王超先生为公司副总经理的 程序符合法律、法规和《公司章程》的有关规定。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 附件：王超先生 ...

证券代码：000623 证券简称：吉林敖东 吉林敖东药业集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | | --- | --- | --- | | 投资者关系活 | | | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 及人员姓名 | 参与本次 2024 年度业绩说明会的投资者 | | | 时间 | 2025 年 4 28 日（星期一）15:00—17:00 | 月 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 副董事长、总经理：郭淑芹 | | | | 独立董事：肖维维 | | | 人员姓名 | 董事、副总经理、财务总监：张淑媛 | | | | 董事、副总经理、董事会秘书：王振宇 | | | | 1、行业以后 ...

2024年，吉林敖东以创新驱动为引领，聚焦医药主业全产业链布局，系统推进中医药传承创新发展，通 过深化"大品种群+多品种群"营销体系战略，精准培育核心产品、强化渠道管控与资源协同共享，实现 医药板块营业收入22.74亿元，展现出强劲发展韧性。 具体来看，中药板块持续发挥支柱效能，以安神补脑液、小儿柴桂退热口服液、血府逐瘀口服液3个核 心品种为引擎，带动重点品种协同发力，实现营业收入16.06亿元；化药板块加速创新成果转化，新品 种加快销售，实现营业收入2.77亿元；医药商业板块优化终端网络布局，连锁药店批发及零售业务实现 营业收入3.91亿元。 吉林敖东相关负责人对《证券日报》记者表示："依托核心大品种销售势能，公司动态优化品种结构， 对重点品种、潜力品种实施精准投入，形成'过亿单品引领、千万级品种支撑、百万级产品蓄力'的梯队 产品矩阵，同步强化基础研究与学术推广双驱动，构建研发转化与市场拓展的营销联动机制，持续夯实 传统中药领域竞争优势，为打造现代化医药产业生态奠定坚实基础。" 加速培育新质生产力 "公司通过传承中药文化精髓与现代科技手段的深度融合，不断探索创新路径，构建了'产学研'深度融 合的创新研发体系 ...

Core Insights - The company reported a total revenue of 2.61 billion yuan in 2024, a decrease of 24.31% compared to 2023, which had a revenue of 3.45 billion yuan [1] - The pharmaceutical sector remains the main revenue driver, contributing 1.88 billion yuan, accounting for 72.11% of total revenue, despite a 27.83% decline from the previous year [1][3] - The company is focusing on key products in its traditional Chinese medicine segment, which includes core products like Anshen Bnna Liquid and Xiaor Chai Gui Oral Liquid, driving significant revenue [3] Revenue Breakdown by Sector - Pharmaceutical revenue: 1,882,395,047.83 yuan (72.11%), down 27.83% from 2,608,458,378.94 yuan [1] - Chain pharmacy wholesale and retail: 391,365,987.46 yuan (14.99%), up 4.36% from 375,020,113.62 yuan [1] - Other business income: 73,862,569.09 yuan (2.83%), up 62.06% from 45,577,260.70 yuan [1] Product Performance - Traditional Chinese medicine sales: 1,605,541,287.90 yuan (61.50%), down 25.42% from 2,152,662,657.59 yuan [1] - Chemical drugs revenue: 276,853,759.93 yuan (10.61%), down 39.26% from 455,795,721.35 yuan [1] - Health products sales reached 2.12 billion yuan, accounting for 8.13% of total revenue [4] Regional Performance - Northeast region: 968,305,996.09 yuan (37.09%), down 14.76% from 1,135,942,714.05 yuan [1] - North region: 377,546,862.16 yuan (14.46%), up 39.78% from 270,101,901.70 yuan [1] - South region: 330,176,089.26 yuan (12.65%), down 20.40% from 414,786,414.20 yuan [1] Sales Strategy and Growth - The company is enhancing its online sales through platforms like JD, Taobao, and Pinduoduo, while also implementing O2O business models in physical stores [4] - The chain pharmacy segment added 183,000 new members, bringing the total to 1.19 million members [3] - The company closed 11 stores and opened 17 new ones, ending the reporting period with a total of 190 stores [3]

外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.31%。 2025年4月23日，吉林敖东(000623.SZ)发布2024年年度报告。截至2025年4月22日，共有235个机构投资 者披露持有吉林敖东A股股份，合计持股量达4.14亿股，占吉林敖东总股本的34.58%。其中，前十大机 构投资者包括敦化市金诚实业有限责任公司、中国农业银行股份有限公司-中证500交易型开放式指数证 券投资基金、香港中央结算有限公司、广东德汇投资管理有限公司-德汇尊享私募证券投资基金、延边 国有资产经营总公司、广东德汇投资管理有限公司-德汇全球优选私募证券投资基金、中国建设银行股 份有限公司-汇添富中证中药交易型开放式指数证券投资基金、广发中证全指医药卫生ETF、富国中证 500指数增强(LOF)A/B、华夏中证500ETF，前十大机构投资者合计持股比例达31.95%。相较于上一季 度，前十大机构持股比例合计下跌了6.05个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即中医药，持股增加占比小幅上涨。本期 较上一季度持股减少的公募基金共计8个，主要包括南方中证50 ...